Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

To treat or not to treat, that is the question: the role of bone-targeted therapy in metastatic prostate cancer.

Higano CS.

J Clin Oncol. 2014 Apr 10;32(11):1107-11. doi: 10.1200/JCO.2013.53.8900. Epub 2014 Mar 3. Erratum in: J Clin Oncol. 2014 Jun 10;32(17):1863.

2.

A case of metastatic cancer with markedly elevated PSA level that was not detected by repeat prostate biopsy.

Iwamura H, Hatakeyama S, Tanaka Y, Tanaka T, Tokui N, Yamamoto H, Imai A, Yoneyama T, Hashimoto Y, Koie T, Yoshikawa K, Ohyama C.

BMC Res Notes. 2014 Jan 29;7:64. doi: 10.1186/1756-0500-7-64.

4.

Should the denosumab metastasis prevention trial change practice for men with nonmetastatic prostate cancer?

Saylor PJ, Michaelson MD.

Oncologist. 2012;17(2):288-90. doi: 10.1634/theoncologist.2011-0433. Epub 2012 Jan 20.

5.
6.

New and emerging therapies for bone metastases in genitourinary cancers.

Saylor PJ, Armstrong AJ, Fizazi K, Freedland S, Saad F, Smith MR, Tombal B, Pienta K.

Eur Urol. 2013 Feb;63(2):309-20. doi: 10.1016/j.eururo.2012.10.007. Epub 2012 Nov 23. Review.

7.

Prostate cancer presenting with normal serum PSA levels and boney metastases treated with zoledronic acid.

Mystakidou K, Katsouda E, Parpa E, Vlahos L.

J Pain Palliat Care Pharmacother. 2005;19(3):41-5.

PMID:
16219610
8.

Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer.

Saylor PJ.

Asian J Androl. 2014 May-Jun;16(3):341-7. doi: 10.4103/1008-682X.122591. Review.

9.

Implications of androgen-deprivation therapy in patients with prostate cancer: A case study.

Doyle-Lindrud S.

Clin J Oncol Nurs. 2006 Oct;10(5):565-6. Review.

PMID:
17063610
10.

[A case of prostate cancer associated with osteolytic bone metastases].

Migita T, Maeda K, Ogata N.

Hinyokika Kiyo. 1999 May;45(5):371-4. Japanese.

PMID:
10410324
11.

Inappropriate treatment of prostate cancer caused by heterophilic antibody interference.

Henry N, Sebe P, Cussenot O.

Nat Clin Pract Urol. 2009 Mar;6(3):164-7. doi: 10.1038/ncpuro1317.

PMID:
19265858
12.

Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.

Miyamoto S, Ito K, Miyakubo M, Suzuki R, Yamamoto T, Suzuki K, Suzuki K, Yamanaka H.

Prostate Cancer Prostatic Dis. 2012 Mar;15(1):75-86. doi: 10.1038/pcan.2011.47. Epub 2011 Oct 11.

PMID:
21986985
13.

Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.

Kamiya N, Suzuki H, Endo T, Takano M, Yano M, Naoi M, Nishimi D, Kawamura K, Imamoto T, Ichikawa T.

Int J Urol. 2012 Feb;19(2):169-73. doi: 10.1111/j.1442-2042.2011.02914.x. Epub 2011 Nov 29.

14.

Preventing bone complications in prostate cancer.

Bishr M, Saad F.

Curr Opin Support Palliat Care. 2012 Sep;6(3):299-303. doi: 10.1097/SPC.0b013e328356da87. Review.

PMID:
22871982
15.

[Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].

Kudlacek S, Puntus T.

Wien Med Wochenschr. 2012 Sep;162(17-18):380-5. doi: 10.1007/s10354-012-0106-z. Epub 2012 Aug 9. Review. German.

PMID:
22875632
16.

[Strategy in advanced castration-resistant prostate cancer].

Gross-Goupil M, Roca S, Pasticier G, Ravaud A.

Bull Cancer. 2012 Jul;99 Suppl 1:S37-45. doi: 10.1684/bdc.2012.1562. Review. French.

PMID:
22522582
17.

Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer.

Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL, Wynne C, Murray R, Zinner NR, Schulman C, Linnartz R, Zheng M, Goessl C, Hei YJ, Small EJ, Cook R, Higano CS.

J Clin Oncol. 2005 May 1;23(13):2918-25.

18.

Prostate cancer: 9. Treatment of advanced disease.

Gleave ME, Bruchovsky N, Moore MJ, Venner P.

CMAJ. 1999 Jan 26;160(2):225-32. Review.

19.

Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinoma.

Figg WD, Kroog G, Duray P, Walther MM, Patronas N, Sartor O, Reed E.

Cancer. 1997 May 15;79(10):1964-8.

PMID:
9149024
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk